A. Pierce

发表

Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus

D. D'cruz, K. Maksimowicz-McKinnon, R. Furie, 2021, Arthritis & rheumatology.

Enhancing enrollment in palliative care trials: key insights from a randomized, placebo-controlled study.

A. Abernethy, D. Currow, J. Bull, 2010, The journal of supportive oncology.

Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.

S. Navarra, K. Maksimowicz-McKinnon, K. Thorneloe, 2020, The Lancet. Rheumatology.

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay

M. Krystal, C. Llamoso, A. Clark, 2020, The Journal of antimicrobial chemotherapy.

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

M. Konopleva, Z. Estrov, Xuelin Huang, 2021 .

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

M. Kozal, P. Cahn, J. Aberg, 2020, The lancet. HIV.

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals

D. Cella, M. Murray, S. Anderson, 2021, The Patient - Patient-Centered Outcomes Research.

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1

M. Kozal, P. Cahn, M. Krystal, 2022, Antimicrobial agents and chemotherapy.

A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.

J. Wurzelmann, B. Lasko, E. Mortensen, 2011, The journal of pain : official journal of the American Pain Society.

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1

M. Kozal, J. Aberg, A. Streinu-Cercel, 2021, AIDS.

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.

M. Kozal, P. Cahn, J. Aberg, 2020, The New England journal of medicine.

A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.

J. Pénzes, E. Spierings, J. Wurzelmann, 2011, The journal of pain : official journal of the American Pain Society.

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain

L. Webster, B. Morlion, J. Peppin, 2008, PAIN®.

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain

L. Webster, B. Morlion, J. Peppin, 2008, PAIN®.